1
|
Zhang X, Zhang F, Chen N, Cui X, Guo X, Sun Z, Guo P, Liao M, Li X. A Rationally Designed H5 Hemagglutinin Subunit Vaccine Provides Broad-Spectrum Protection against Various H5Nx Highly Pathogenic Avian Influenza Viruses in Chickens. Vaccines (Basel) 2024; 12:932. [PMID: 39204055 PMCID: PMC11359994 DOI: 10.3390/vaccines12080932] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2024] [Revised: 08/14/2024] [Accepted: 08/19/2024] [Indexed: 09/03/2024] Open
Abstract
The evolution of the H5 highly pathogenic avian influenza (HPAI) viruses has led to the emergence of distinct groups with genetically similar clusters of hemagglutinin (HA) sequences. In this study, a consensus H5 HA sequence was cloned into the baculovirus expression system. The HA protein was expressed in baculovirus-infected insect cells and utilized as the antigen for the production of an oil emulsion-based H5 avian influenza vaccine (rBacH5Con5Mut). Twenty-one-day-old SPF chickens were immunized with this vaccine and then challenged at 21 days post-vaccination with clade 2.3.2.1, clade 2.3.4.4, and clade 7.2 of H5 HPAI viruses. The sera of vaccinated chickens exhibited high hemagglutination inhibition (HI) titers against the rBacH5 vaccine antigen, while lower HI titers were observed against the different challenge virus H5 hemagglutinins. Furthermore, the rBacH5Con5Mut vaccine provided 100% protection from mortality and clinical signs. Virus isolation results showed that oropharyngeal and cloacal shedding was prevented in 100% of the vaccinated chickens when challenged with clade 2.3.2.1 and clade 2.3.4.4 H5 viruses. When the rBacH5Con5Mut vaccine candidate was administrated at one day of age, 100% protection was demonstrated against the challenge of clade 2.3.4.4 virus at three weeks of age, indicating the potential of this vaccine for hatchery vaccination. Overall, A single immunization of rBacH5Con5Mut vaccine candidate with a consensus HA antigen can protect chickens against different clades of H5 HPAI viruses throughout the rearing period of broiler chickens without a boost, thus fulfilling the criteria for an efficacious broad-spectrum H5 avian influenza vaccine.
Collapse
Affiliation(s)
- Xuxiao Zhang
- Boehringer Ingelheim Vetmedica (China) Co., Ltd., Taizhou 225300, China; (X.Z.); (F.Z.); (X.G.); (Z.S.); (P.G.)
| | - Fushou Zhang
- Boehringer Ingelheim Vetmedica (China) Co., Ltd., Taizhou 225300, China; (X.Z.); (F.Z.); (X.G.); (Z.S.); (P.G.)
- National and Regional Joint Engineering Laboratory for Medicament of Zoonosis Prevention and Control, College of Veterinary Medicine, South China Agricultural University, Guangzhou 510642, China
| | - Ning Chen
- Boehringer Ingelheim Vetmedica (China) Co., Ltd., Taizhou 225300, China; (X.Z.); (F.Z.); (X.G.); (Z.S.); (P.G.)
| | - Xiaoping Cui
- Boehringer Ingelheim Animal Health USA Inc., 3239 Satellite Blvd, Duluth, GA 30096, USA;
| | - Xiaoqin Guo
- Boehringer Ingelheim Vetmedica (China) Co., Ltd., Taizhou 225300, China; (X.Z.); (F.Z.); (X.G.); (Z.S.); (P.G.)
| | - Zhi Sun
- Boehringer Ingelheim Vetmedica (China) Co., Ltd., Taizhou 225300, China; (X.Z.); (F.Z.); (X.G.); (Z.S.); (P.G.)
| | - Pengju Guo
- Boehringer Ingelheim Vetmedica (China) Co., Ltd., Taizhou 225300, China; (X.Z.); (F.Z.); (X.G.); (Z.S.); (P.G.)
| | - Ming Liao
- National and Regional Joint Engineering Laboratory for Medicament of Zoonosis Prevention and Control, College of Veterinary Medicine, South China Agricultural University, Guangzhou 510642, China
- Key Laboratory for Prevention and Control of Avian Influenza and Other Major Poultry Diseases, Ministry of Agriculture and Rural Affairs, Institute of Animal Health, Guangdong Academy of Agricultural Sciences, Guangzhou 510640, China
- College of Animal Science and Technology, Zhongkai University of Agricultural and Engineering, Guangzhou 510550, China
| | - Xin Li
- Boehringer Ingelheim Vetmedica (China) Co., Ltd., Taizhou 225300, China; (X.Z.); (F.Z.); (X.G.); (Z.S.); (P.G.)
| |
Collapse
|
2
|
Ravikumar R, Chan J, Prabakaran M. Vaccines against Major Poultry Viral Diseases: Strategies to Improve the Breadth and Protective Efficacy. Viruses 2022; 14:v14061195. [PMID: 35746665 PMCID: PMC9230070 DOI: 10.3390/v14061195] [Citation(s) in RCA: 15] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2022] [Revised: 05/27/2022] [Accepted: 05/28/2022] [Indexed: 12/24/2022] Open
Abstract
The poultry industry is the largest source of meat and eggs for human consumption worldwide. However, viral outbreaks in farmed stock are a common occurrence and a major source of concern for the industry. Mortality and morbidity resulting from an outbreak can cause significant economic losses with subsequent detrimental impacts on the global food supply chain. Mass vaccination is one of the main strategies for controlling and preventing viral infection in poultry. The development of broadly protective vaccines against avian viral diseases will alleviate selection pressure on field virus strains and simplify vaccination regimens for commercial farms with overall savings in husbandry costs. With the increasing number of emerging and re-emerging viral infectious diseases in the poultry industry, there is an urgent need to understand the strategies for broadening the protective efficacy of the vaccines against distinct viral strains. The current review provides an overview of viral vaccines and vaccination regimens available for common avian viral infections, and strategies for developing safer and more efficacious viral vaccines for poultry.
Collapse
|
3
|
Lei H, Gao T, Cen Q, Peng X. Haemagglutinin displayed on the surface of Lactococcus lactis confers broad cross-clade protection against different H5N1 viruses in chickens. Microb Cell Fact 2020; 19:193. [PMID: 33059676 PMCID: PMC7557258 DOI: 10.1186/s12934-020-01453-7] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/02/2020] [Accepted: 10/09/2020] [Indexed: 01/01/2023] Open
Abstract
Background The highly pathogenic avian influenza (HPAI) H5N1 virus poses a potential threat to the poultry industry. The currently available avian influenza H5N1 vaccines for poultry are clade-specific. Therefore, an effective vaccine for preventing and controlling H5N1 viruses belonging to different clades needs to be developed. Results Recombinant L. lactis/pNZ8148-Spax-HA was generated, and the influenza virus haemagglutinin (HA) protein of A/Vietnam/1203/2004 (H5N1) was displayed on the surface of Lactococcus lactis (L. lactis). Spax was used as an anchor protein. Chickens vaccinated orally with unadjuvanted L. lactis/pNZ8148-Spax-HA could produce significant humoral and mucosal responses and neutralizing activities against H5N1 viruses belonging to different clades. Importantly, unadjuvanted L. lactis/pNZ8148-Spax-HA conferred cross-clade protection against lethal challenge with different H5N1 viruses in the chicken model. Conclusion This study provides insights into the cross-clade protection conferred by unadjuvanted L. lactis/pNZ8148-Spax-HA, and the results might help the establishment of a promising platform for the development of a safe and effective H5N1 cross-clade vaccine for poultry.
Collapse
Affiliation(s)
- Han Lei
- College of Medicine, Southwest Jiaotong University, Chengdu, 610031, Sichuan, China.
| | - Tong Gao
- College of Medicine, Southwest Jiaotong University, Chengdu, 610031, Sichuan, China
| | - Qianhong Cen
- College of Medicine, Southwest Jiaotong University, Chengdu, 610031, Sichuan, China
| | - Xiaojue Peng
- Department of Biotechnology, College of Life Science, Nanchang University, Jiangxi, 330031, China
| |
Collapse
|
4
|
Kim HM, Kim DY, Kang YM, Cho HK, Lee CH, Choi SH, Lee H, Bae YC, Lee MH, Kang HM. Immunogenicity and protective efficacy of clade 2.3.2.1c and clade 2.3.4.4c H5Nx avian influenza antigen bank vaccines in mice, Korea. Vaccine 2020; 38:6080-6087. [PMID: 32732143 DOI: 10.1016/j.vaccine.2020.07.033] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2020] [Revised: 07/14/2020] [Accepted: 07/16/2020] [Indexed: 12/15/2022]
Affiliation(s)
- Hyun-Mi Kim
- Avian Influenza Vaccine Research Laboratory, Avian Influenza Research and Diagnostic Division, Animal and Plant Quarantine Agency, Gimcheon, Republic of Korea
| | - Do-Young Kim
- Avian Influenza Vaccine Research Laboratory, Avian Influenza Research and Diagnostic Division, Animal and Plant Quarantine Agency, Gimcheon, Republic of Korea
| | - Yong-Myung Kang
- Avian Influenza Vaccine Research Laboratory, Avian Influenza Research and Diagnostic Division, Animal and Plant Quarantine Agency, Gimcheon, Republic of Korea
| | - Hyun-Kyu Cho
- Avian Influenza Vaccine Research Laboratory, Avian Influenza Research and Diagnostic Division, Animal and Plant Quarantine Agency, Gimcheon, Republic of Korea
| | - Chi-Ho Lee
- Avian Influenza Vaccine Research Laboratory, Avian Influenza Research and Diagnostic Division, Animal and Plant Quarantine Agency, Gimcheon, Republic of Korea
| | - Sang-Hyun Choi
- Avian Influenza Vaccine Research Laboratory, Avian Influenza Research and Diagnostic Division, Animal and Plant Quarantine Agency, Gimcheon, Republic of Korea
| | - Hyunkyoung Lee
- Pathologic Diagnostic Laboratory, Animal Disease Diagnostic Division, Animal and Plant Quarantine Agency, Gimcheon, Republic of Korea
| | - You-Chan Bae
- Pathologic Diagnostic Laboratory, Animal Disease Diagnostic Division, Animal and Plant Quarantine Agency, Gimcheon, Republic of Korea
| | - Myoung-Heon Lee
- Avian Influenza Vaccine Research Laboratory, Avian Influenza Research and Diagnostic Division, Animal and Plant Quarantine Agency, Gimcheon, Republic of Korea
| | - Hyun-Mi Kang
- Avian Influenza Vaccine Research Laboratory, Avian Influenza Research and Diagnostic Division, Animal and Plant Quarantine Agency, Gimcheon, Republic of Korea.
| |
Collapse
|
5
|
Xu H, Wang Y, Han G, Fang W, He F. Identification of E2 with improved secretion and immunogenicity against CSFV in piglets. BMC Microbiol 2020; 20:26. [PMID: 32019519 PMCID: PMC7001342 DOI: 10.1186/s12866-020-1713-2] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2019] [Accepted: 01/27/2020] [Indexed: 01/16/2023] Open
Abstract
BACKGROUND Outbreaks of Classical swine fever virus (CSFV) cause significant economic losses in the swine industry. Vaccination is the major method to prevent and control the disease. As live attenuated vaccines fail to elicit differentiable immunity between infected and vaccinated animals, subunit vaccine was considered as an alternative candidate to prevent and eradicate CSFV. Subunit vaccines present advantages in DIVA immunogenicity and safety. The technology was limited due to the low yield and the high cost with multiple and large doses. The native E2 signal peptide has not been well defined before. Here, the aim of this study is to develop a cost-effective and efficacious E2 vaccine candidate against CSFV with signal peptide and E2 sequence selection. RESULTS A novel CSFV E2 sequence (E2ZJ) was identified from an epidemic strain of Zhejiang for outstanding secretion in baculovirus and enhanced immunogenicity. E2 secretion induced with the selected signal peptide, SPZJ (SP23), increase at least 50% as compared to any other signal peptides tested. Besides, unique antigenic features were identified in E2ZJ. As indicated with immunized sera in IFA against CSFV infection, E2ZJ elicited CSFV antibodies at the earlier stage than other E2 types tested in mice. Moreover, higher level of neutralizing and CSFV antibodies against CSFV with E2ZJ was detected than other E2s with the same dosage at 28 dpi. Further, E2ZJ successfully elicited neutralizing immunity in piglets. A single dose of 5 μg of E2ZJ was sufficient to induce protective antibodies against CSFV in piglets and provided 100% protection against lethal virus challenge. CONCLUSIONS Our studies provide evidence that E2ZJ guided by a novel E2 signal peptide (SPZJ) was efficiently secreted and presented significantly improved immunogenicity than conventional E2 vaccines. Moreover, a single dose of 5 μg E2ZJ is efficacious against CSFV in piglets.
Collapse
Affiliation(s)
- Huiling Xu
- Institute of Preventive Veterinary Medicine, College of Animal Sciences of Zhejiang University, 866 Yuhangtang road, Hangzhou, 310058, China.,Zhejiang Provincial Key Laboratory of Preventive Veterinary Medicine, Hangzhou, China
| | - Yanli Wang
- Institute of Preventive Veterinary Medicine, College of Animal Sciences of Zhejiang University, 866 Yuhangtang road, Hangzhou, 310058, China.,Zhejiang Provincial Key Laboratory of Preventive Veterinary Medicine, Hangzhou, China
| | - Guangwei Han
- Institute of Preventive Veterinary Medicine, College of Animal Sciences of Zhejiang University, 866 Yuhangtang road, Hangzhou, 310058, China.,Zhejiang Provincial Key Laboratory of Preventive Veterinary Medicine, Hangzhou, China
| | - Weihuan Fang
- Institute of Preventive Veterinary Medicine, College of Animal Sciences of Zhejiang University, 866 Yuhangtang road, Hangzhou, 310058, China.,Zhejiang Provincial Key Laboratory of Preventive Veterinary Medicine, Hangzhou, China
| | - Fang He
- Institute of Preventive Veterinary Medicine, College of Animal Sciences of Zhejiang University, 866 Yuhangtang road, Hangzhou, 310058, China. .,Zhejiang Provincial Key Laboratory of Preventive Veterinary Medicine, Hangzhou, China.
| |
Collapse
|
6
|
Jeong JH, Kim EH, Lloren KKS, Kwon JJ, Kwon HI, Ahn SJ, Kim YI, Choi WS, Si YJ, Lee OJ, Han HJ, Baek YH, Song MS, Choi YK, Kim CJ. Preclinical evaluation of the efficacy of an H5N8 vaccine candidate (IDCDC-RG43A) in mouse and ferret models for pandemic preparedness. Vaccine 2018; 37:484-493. [PMID: 30502069 DOI: 10.1016/j.vaccine.2018.11.064] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2018] [Revised: 11/09/2018] [Accepted: 11/20/2018] [Indexed: 12/14/2022]
Abstract
Because H5N1 influenza viruses continuously threaten the public health, the WHO has prepared various clades of H5N1 mock-up vaccines as one of the measures for pandemic preparedness. The recent worldwide outbreak of H5Nx virus which belongs to clade 2.3.4.4 and of which H5N6 subtype belongs and already caused human infection also increases the need of pandemic vaccine for such novel emerging viruses. In this study, we evaluated the protective efficacy and immunogenicity of an egg-based and inactivated whole-virus H5N8 (IDCDC-RG43A) developed by CDC containing HA and NA gene of the parent virus A/gyrfalcon/Washington/41088-6/2014. Mice vaccinated two times elicited low to moderate antibody titer in varying amount of antigen doses against the homologous H5N8 vaccine virus and heterologous intra-clade 2.3.4.4 H5N6 (A/Sichuan/26221/2014) virus. Mice immunized with at least 3.0 µg/dose of IDCDC-RG43A with aluminum hydroxide adjuvant were completely protected from lethal challenge with the mouse-adapted H5N8 (A/Environment/Korea/ma468/2015, maH5N8) as well as cleared the viral replication in tissues including lung, brain, spleen, and kidney. Vaccinated ferrets induced high antibody titers against clade 2.3.4.4 H5N8/H5N6 viruses and the antibody showed high cross-reactivity to clade 2.2 H5N1 but not to clade 1 and 2.3.4 viruses as measured by hemagglutinin inhibition and serum neutralization assays. Furthermore, administration of the vaccine in ferrets resulted in attenuation of clinical disease signs and virus spread to peripheral organs including lung, spleen, and kidney from high dose challenge with maH5N8 virus. The protective and immunogenic characteristic of the candidate vaccine are essential attributes to be considered for further clinical trials as a pre-pandemic vaccine for a potential pandemic virus.
Collapse
Affiliation(s)
- Ju Hwan Jeong
- Department of Microbiology, Chungbuk National University College of Medicine and Medical Research Institute, Cheongju, Republic of Korea
| | - Eun-Ha Kim
- Department of Microbiology, Chungbuk National University College of Medicine and Medical Research Institute, Cheongju, Republic of Korea
| | - Khristine Kaith S Lloren
- Department of Microbiology, Chungbuk National University College of Medicine and Medical Research Institute, Cheongju, Republic of Korea
| | - Jin Jung Kwon
- Department of Microbiology, Chungbuk National University College of Medicine and Medical Research Institute, Cheongju, Republic of Korea
| | - Hyeok-Il Kwon
- Department of Microbiology, Chungbuk National University College of Medicine and Medical Research Institute, Cheongju, Republic of Korea
| | - Su Jeong Ahn
- Department of Microbiology, Chungbuk National University College of Medicine and Medical Research Institute, Cheongju, Republic of Korea
| | - Young-Il Kim
- Department of Microbiology, Chungbuk National University College of Medicine and Medical Research Institute, Cheongju, Republic of Korea
| | - Won-Suk Choi
- Department of Microbiology, Chungbuk National University College of Medicine and Medical Research Institute, Cheongju, Republic of Korea
| | - Young-Jae Si
- Department of Microbiology, Chungbuk National University College of Medicine and Medical Research Institute, Cheongju, Republic of Korea
| | - Ok-Jun Lee
- Department of Microbiology, Chungbuk National University College of Medicine and Medical Research Institute, Cheongju, Republic of Korea
| | - Hae Jung Han
- Department of Microbiology, Chungbuk National University College of Medicine and Medical Research Institute, Cheongju, Republic of Korea; Research & Development Center, Green Cross Corporation, Yongin, Republic of Korea; Research & Development Center, Green Cross Wellbeing Corporation, Seongnam, Republic of Korea
| | - Yun Hee Baek
- Department of Microbiology, Chungbuk National University College of Medicine and Medical Research Institute, Cheongju, Republic of Korea
| | - Min-Suk Song
- Department of Microbiology, Chungbuk National University College of Medicine and Medical Research Institute, Cheongju, Republic of Korea.
| | - Young Ki Choi
- Department of Microbiology, Chungbuk National University College of Medicine and Medical Research Institute, Cheongju, Republic of Korea.
| | - Chul-Joong Kim
- College of Veterinary Medicine, Chungnam National University, Daejeon, Republic of Korea.
| |
Collapse
|
7
|
Jiang Y, Yang G, Wang Q, Wang Z, Yang W, Gu W, Shi C, Wang J, Huang H, Wang C. Molecular mechanisms underlying protection against H9N2 influenza virus challenge in mice by recombinant Lactobacillus plantarum with surface displayed HA2-LTB. J Biotechnol 2017; 259:6-14. [PMID: 28811215 DOI: 10.1016/j.jbiotec.2017.08.011] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2017] [Revised: 07/24/2017] [Accepted: 08/09/2017] [Indexed: 12/29/2022]
Abstract
It has been considered that the Avian influenza virus (AIV) causes severe threats to poultry industry. In this study, we constructed a series of recombinant Lactobacillus plantarum (L. plantarum) with surface displayed hemagglutinin subunit 2 (HA2) alone or together with heat-labile toxin B subunit (LTB) from enterotoxigenic Escherichia coli. Balb/c mice were used as model to evaluate the protective effects of recombinant L. plantarum strains against H9N2 subtype challenge. The results showed that the presence of LTB significantly increased the percentages of CD3+CD4+IL-4+, CD3+CD4+IFN-γ+ and CD3+CD4+IL-17+ T cells, as well as CD3+CD8+IFN-γ+ T cells in spleen and MLNs determined by Fluorescence-Activated Cell Sorting assay. Similar increased production of serum IFN-γ was also confirmed by enzyme linked immunosorbent assay (ELISA). The L. plantarum with surface displayed HA2-LTB also dramatically increased the percentages of B220+ IgA+ B cells in peyer patch, in consistent with elevated production of mucosal SIgA antibody determined by ELISA. Finally, the orally administrated HA2-LTB expressing strain efficiently protected mice against H9N2 subtype AIV challenge shown by increased survival percentages, body weight gains and decreased lung lesions in histopathologic analysis. In conclusion, this study provides more detail mechanisms underlying the adjuvant effects of LTB on heterologous antigen produced in recombinant lactic acid bacteria.
Collapse
Affiliation(s)
- Yanlong Jiang
- College of Animal Science and Technology, Jilin Provincial Engineering Research Center of Animal Probiotics, Key Laboratory of Animal Production and Product Quality Safety of Ministry of Education, Jilin Agricultural University, Changchun, 130118, China
| | - Guilian Yang
- College of Animal Science and Technology, Jilin Provincial Engineering Research Center of Animal Probiotics, Key Laboratory of Animal Production and Product Quality Safety of Ministry of Education, Jilin Agricultural University, Changchun, 130118, China
| | - Qi Wang
- College of Animal Science and Technology, Jilin Provincial Engineering Research Center of Animal Probiotics, Key Laboratory of Animal Production and Product Quality Safety of Ministry of Education, Jilin Agricultural University, Changchun, 130118, China
| | - Zhannan Wang
- College of Animal Science and Technology, Jilin Provincial Engineering Research Center of Animal Probiotics, Key Laboratory of Animal Production and Product Quality Safety of Ministry of Education, Jilin Agricultural University, Changchun, 130118, China
| | - Wentao Yang
- College of Animal Science and Technology, Jilin Provincial Engineering Research Center of Animal Probiotics, Key Laboratory of Animal Production and Product Quality Safety of Ministry of Education, Jilin Agricultural University, Changchun, 130118, China
| | - Wei Gu
- College of Animal Science and Technology, Jilin Provincial Engineering Research Center of Animal Probiotics, Key Laboratory of Animal Production and Product Quality Safety of Ministry of Education, Jilin Agricultural University, Changchun, 130118, China; Shandong Baolai-Leelai Bio-Tech Co., LTD, Taian, Shandong Province, 171000, China
| | - Chunwei Shi
- College of Animal Science and Technology, Jilin Provincial Engineering Research Center of Animal Probiotics, Key Laboratory of Animal Production and Product Quality Safety of Ministry of Education, Jilin Agricultural University, Changchun, 130118, China
| | - Jianzhong Wang
- College of Animal Science and Technology, Jilin Provincial Engineering Research Center of Animal Probiotics, Key Laboratory of Animal Production and Product Quality Safety of Ministry of Education, Jilin Agricultural University, Changchun, 130118, China
| | - Haibin Huang
- College of Animal Science and Technology, Jilin Provincial Engineering Research Center of Animal Probiotics, Key Laboratory of Animal Production and Product Quality Safety of Ministry of Education, Jilin Agricultural University, Changchun, 130118, China
| | - Chunfeng Wang
- College of Animal Science and Technology, Jilin Provincial Engineering Research Center of Animal Probiotics, Key Laboratory of Animal Production and Product Quality Safety of Ministry of Education, Jilin Agricultural University, Changchun, 130118, China.
| |
Collapse
|
8
|
Effective in vivo therapeutic IgG antibody against VP3 of enterovirus 71 with receptor-competing activity. Sci Rep 2017; 7:46402. [PMID: 28422137 PMCID: PMC5395816 DOI: 10.1038/srep46402] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2016] [Accepted: 03/17/2017] [Indexed: 11/23/2022] Open
Abstract
Passive immunization is an effective option for treatment against hand, foot and mouth disease caused by EV71, especially with cross-neutralizing IgG monoclonal antibodies. In this study, an EV71-specific IgG2a antibody designated 5H7 was identified and characterized. 5H7 efficiently neutralizes the major EV71 genogroups (A, B4, C2, C4). The conformational epitope of 5H7 was mapped to the highly conserved amino acid position 74 on VP3 capsid protein using escape mutants. Neutralization with 5H7 is mediated by the inhibition of viral attachment, as revealed by virus-binding and post-attachment assays. In a competitive pull-down assay with SCARB2, 5H7 blocks the receptor-binding site on EV71 for virus neutralization. Passive immunization of chimeric 5H7 protected 100% of two-week-old AG129 mice from lethal challenge with an EV71 B4 strain for both prophylactic and therapeutic treatments. In contrast, 10D3, a previously reported neutralizing antibody that takes effect after virus attachment, could only confer prophylactic protection. These results indicate that efficient interruption of viral attachment is critical for effective therapeutic activity with 5H7. This report documents a novel universal neutralizing IgG antibody for EV71 therapeutics and reveals the underlying mechanism.
Collapse
|
9
|
Oliveira Cavalcanti M, Vaughn E, Capua I, Cattoli G, Terregino C, Harder T, Grund C, Vega C, Robles F, Franco J, Darji A, Arafa AS, Mundt E. A genetically engineered H5 protein expressed in insect cells confers protection against different clades of H5N1 highly pathogenic avian influenza viruses in chickens. Avian Pathol 2017; 46:224-233. [PMID: 27807985 DOI: 10.1080/03079457.2016.1250866] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
The evolution of highly pathogenic H5N1 avian influenza viruses (HPAI-H5N1) has resulted in the appearance of a number of diverse groups of HPAI-H5N1 based on the presence of genetically similar clusters of their haemagglutinin sequences (clades). An H5 antigen encoded by a recombinant baculovirus and expressed in insect cells was used for oil-emulsion-based vaccine prototypes. In several experiments, vaccination was performed at 10 days of age, followed by challenge infection on day 21 post vaccination (PV) with HPAI-H5N1 clades 2.2, 2.2.1, and 2.3.2. A further challenge infection with HPAI-H5N1 clade 2.2.1 was performed at day 42 PV. High haemagglutination inhibition titres were observed for the recH5 vaccine antigen, and lower haemagglutination inhibition titres for the challenge virus antigens. Nevertheless, the rate of protection from mortality and clinical signs was 100% when challenged at 21 days PV and 42 days PV, indicating protection over the entire broiler chicken rearing period without a second vaccination. The unvaccinated control chickens mostly died between two and five days after challenge infection. A low level of viral RNA was detected by reverse transcription followed by a quantitative polymerase chain reaction in a limited number of birds for a short period after challenge infection, indicating a limited spread of HPAI-H5N1 at flock level. Furthermore, it was observed that the vaccine can be used in a differentiation infected from vaccinated animals (DIVA) approach, based on the detection of nucleoprotein antibodies in vaccinated/challenged chickens. The vaccine fulfilled all expectations of an inactivated vaccine after one vaccination against challenge with different clades of H5N1-HPAI and is suitable for a DIVA approach.
Collapse
Affiliation(s)
| | - Eric Vaughn
- b Boehringer Ingelheim Vetmedica, Inc. , Ames , IA , USA
| | - Ilaria Capua
- c OIE/FAO and National Reference Laboratory for Newcastle Disease and Avian Influenza , Istituto Zooprofilattico Sperimentale delle Venezie, Viale dell'Università , Legnaro , Italy
| | - Giovanni Cattoli
- c OIE/FAO and National Reference Laboratory for Newcastle Disease and Avian Influenza , Istituto Zooprofilattico Sperimentale delle Venezie, Viale dell'Università , Legnaro , Italy
| | - Calogero Terregino
- c OIE/FAO and National Reference Laboratory for Newcastle Disease and Avian Influenza , Istituto Zooprofilattico Sperimentale delle Venezie, Viale dell'Università , Legnaro , Italy
| | - Timm Harder
- d Friedrich-Loeffler-Institut, Federal Research Institute for Animal Health , Greifswald-Insel Riems , Germany
| | - Christian Grund
- d Friedrich-Loeffler-Institut, Federal Research Institute for Animal Health , Greifswald-Insel Riems , Germany
| | - Carlos Vega
- e Boehringer Ingelheim Vetmedica, S.A. de C.V , Guadalajara , Mexico
| | - Francisco Robles
- e Boehringer Ingelheim Vetmedica, S.A. de C.V , Guadalajara , Mexico
| | - Julio Franco
- e Boehringer Ingelheim Vetmedica, S.A. de C.V , Guadalajara , Mexico
| | - Ayub Darji
- f Centre de Recerca en Sanitat Animal , CReSA, UAB-IRTA , Barcelona , Spain
| | - Abdel-Satar Arafa
- g National Laboratory for Veterinary Quality Control on Poultry Production , Animal Health Research Institute , Giza , Egypt
| | - Egbert Mundt
- a Boehringer Ingelheim Veterinary Research Center , Hannover , Germany
| |
Collapse
|
10
|
He F, Leyrer S, Kwang J. Strategies towards universal pandemic influenza vaccines. Expert Rev Vaccines 2015; 15:215-25. [DOI: 10.1586/14760584.2016.1115352] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- Fang He
- Animal Health Biotechnology, Temasek Life Sciences Laboratory, Singapore, Singapore
| | - Sonja Leyrer
- Emergent Product Development Germany GmbH, Munich, Germany
| | - Jimmy Kwang
- Animal Health Biotechnology, Temasek Life Sciences Laboratory, Singapore, Singapore
- Department of Microbiology, Faculty of Medicine, National University of Singapore, Singapore, Singapore
| |
Collapse
|
11
|
Abstract
Influenza outbreaks by highly pathogenic avian influenza viruses, such as H5N1, have caused significant morbidity and mortality in poultry and mammals. Though the risk of community-level spread of highly pathogenic avian influenza (HPAI) remains to be low since the transmission of influenza virus from animals to humans is not common, HPAI may acquire changes in receptor-binding specificity that lead to human to human transmission. Cases of sporadic infection in humans have been increasing every year and the continuous spread has posed a threat to animal and human health. Vaccination remains to be the most effective strategy to prevent and control the spread of influenza viruses. Other than conventional inactivated whole virus vaccine, several vaccine strategies have been adopted in order to universally defend against H5N1s infection, including subunit vaccine, viral vector-based vaccine, chimeric epitope vaccine strains and HA stalk-based vaccine.
Collapse
Affiliation(s)
- Yunrui Tan
- Animal Health Biotechnology, Temasek Life Sciences Laboratory, 1 Research Link, National University of Singapore, Singapore, 117604, Singapore
| | - Fang He
- Animal Health Biotechnology, Temasek Life Sciences Laboratory, 1 Research Link, National University of Singapore, Singapore, 117604, Singapore
| | - Jimmy Kwang
- Animal Health Biotechnology, Temasek Life Sciences Laboratory, 1 Research Link, National University of Singapore, Singapore, 117604, Singapore.,Department of Microbiology Faculty of Medicine, National University of Singapore, Singapore
| |
Collapse
|
12
|
A novel humanized antibody neutralizes H5N1 influenza virus via two different mechanisms. J Virol 2015; 89:3712-22. [PMID: 25609802 DOI: 10.1128/jvi.03014-14] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
UNLABELLED Highly pathogenic avian influenza virus subtype H5N1 continues to be a severe threat to public health, as well as the poultry industry, because of its high lethality and antigenic drift rate. Neutralizing monoclonal antibodies (MAbs) can serve as a useful tool for preventing, treating, and detecting H5N1. In the present study, humanized H5 antibody 8A8 was developed from a murine H5 MAb. Both the humanized and mouse MAbs presented positive activity in hemagglutination inhibition (HI), virus neutralization, and immunofluorescence assays against a wide range of H5N1 strains. Interestingly, both human and murine 8A8 antibodies were able to detect H5 in Western blot assays under reducing conditions. Further, by sequencing of escape mutants, the conformational epitope of 8A8 was found to be located within the receptor binding domain (RBD) of H5. The linear epitope of 8A8 was identified by Western blotting of overlapping fragments and substitution mutant forms of HA1. Reverse genetic H5N1 strains with individual mutations in either the conformational or the linear epitope were generated and characterized in a series of assays, including HI, postattachment, and cell-cell fusion inhibition assays. The results indicate that for 8A8, virus neutralization mediated by RBD blocking relies on the conformational epitope while binding to the linear epitope contributes to the neutralization by inhibiting membrane fusion. Taken together, the results of this study show that a novel humanized H5 MAb binds to two types of epitopes on HA, leading to virus neutralization via two mechanisms. IMPORTANCE Recurrence of the highly pathogenic avian influenza virus subtype H5N1 in humans and poultry continues to be a serious public health concern. Preventive and therapeutic measures against influenza A viruses have received much interest in the context of global efforts to combat the current and future pandemics. Passive immune therapy is considered to be the most effective and economically prudent preventive strategy against influenza virus besides vaccination. It is important to develop a humanized neutralizing monoclonal antibody (MAb) against all of the clades of H5N1. For the first time, we report in this study that a novel humanized H5 MAb binds to two types of epitopes on HA, leading to virus neutralization via two mechanisms. These findings further deepen our understanding of influenza virus neutralization.
Collapse
|